May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
A Comparison of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution and the Concomitant Administration of TRAVATAN® and Timolol 0.5%
Author Affiliations & Notes
  • B.A. Hughes
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • M.S. Juzych
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • M.Y. Alexander
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • S.C. Pettigrew
    Alcon Research Ltd., Fort Worth, TX
  • R.M. Andrew
    Alcon Research Ltd., Fort Worth, TX
  • E.K. Sullivan
    Alcon Research Ltd., Fort Worth, TX
  • S. Mallick
    Alcon Research Ltd., Fort Worth, TX
  • T.A. Landry
    Alcon Research Ltd., Fort Worth, TX
  • M.V. W. Bergamini
    Alcon Research Ltd., Fort Worth, TX
  • S.M. Robertson
    Alcon Research Ltd., Fort Worth, TX
  • Footnotes
    Commercial Relationships  B.A. Hughes, Alcon Research, Ltd. F; M.S. Juzych, Alcon Research, Ltd. F; M.Y. Alexander, Alcon Research, Ltd. F; S.C. Pettigrew, Alcon Research, Ltd. E; R.M. Andrew, Alcon Research, Ltd. E; E.K. Sullivan, Alcon Research, Ltd. E; S. Mallick, Alcon Research, Ltd. E; T.A. Landry, Alcon Research, Ltd. E; M.V.W. Bergamini, Alcon Research, Ltd. E; S.M. Robertson, Alcon Research, Ltd. E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4479. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B.A. Hughes, M.S. Juzych, M.Y. Alexander, S.C. Pettigrew, R.M. Andrew, E.K. Sullivan, S. Mallick, T.A. Landry, M.V. W. Bergamini, S.M. Robertson; A Comparison of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution and the Concomitant Administration of TRAVATAN® and Timolol 0.5% . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4479.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare the IOP–lowering efficacy of the fixed combination of Travoprost 0.004%/Timolol 0.5% (Trav/Tim) to the concomitant administration of TRAVATAN® and Timolol 0.5% (Trav + Tim). Methods: This was a double–masked, randomized, parallel group multi–site study in patients with open–angle glaucoma or ocular hypertension. Following a wash–out of 5 days to 4 weeks from their previous ocular hypotensive medications, patients’ baseline IOPs were measured at 8 am, 10 am, and 4 PM. Entry IOP was 22–36 mmHg at 8 am on two separate eligibility visits. Follow–up treatment visits were conducted at Week 2, Week 6, and Month 3. Patients were randomized to either Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution (Trav/Tim) am plus Timolol vehicle PM (n=151) or Timolol am plus TRAVATAN® PM (Trav + Tim)(n=142). Statistical analyses were based on ANOVA using SAS for Windows 8.2. Results: Results demonstrate that the fixed combination of Trav/Tim reduced IOP from baseline 7.4–9.4 mmHg (32–37%) compared to 8.4–9.4 mmHg (36–38%) by the concomitant administration of Trav + Tim. Treatment group differences in mean IOP ranged from 0.1 to 1.0 mmHg. A secondary outcome demonstrated that Trav/Tim provides clinically relevant IOP control throughout the day with up to 83% of patients achieving IOP <18 mmHg, with 34% of patients treated with Trav/Tim maintaining IOP <18 mmHg at all nine visits and times throughout the three–month period. Additionally, both Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution and the concomitant administration of TRAVATAN and Timolol 0.5% demonstrated diurnal intraocular pressure control with differences in mean diurnal intraocular pressures ranging from 0.3 to 0.9 mmHg versus 1.1 to 1.3 mmHg, respectively. Conclusions: Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution dosed once daily in the morning produces IOP–lowering efficacy that is similar to the concomitant administration of TRAVATAN plus Timolol 0.5%.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • intraocular pressure • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×